JSPR Oct 2024 12.500 put
| Previous close | 1.8700 |
| Open | N/A |
| Bid | 0.1500 |
| Ask | 5.0000 |
| Strike | 12.50 |
| Expiry date | 2024-10-18 |
| Day's range | 1.8700 - 1.8700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireJasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study
- GlobeNewswire
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference
- GlobeNewswire
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to BEACON study Initial data from BEACON study through 240mg dosing cohort to be presented in 4Q24 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy
